Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT07127900

Diaphragmatic Evaluation by Fluoroscopy to Identify Phrenic Nerve Dysfunction Related to Electroporation

Define-PFA: Diaphragmatic Evaluation by Fluoroscopy to Identify Phrenic Nerve Dysfunction Related to Electroporation

Status
Withdrawn
Phase
Study type
Observational
Enrollment
0 (actual)
Sponsor
Laurent Macle · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This study aims to better understand the potential side effects of a heart treatment called PFA (Pulsed Field Ablation), used to treat an arrhythmia known as atrial fibrillation. This technique has already been in clinical use for several years. The goal of the study is to detect a possible adverse effect of this procedure: injury to the phrenic nerve, which could result in paralysis of one side of the diaphragm. The diaphragm is an important muscle for breathing and can occasionally be affected during certain cardiac ablation procedures. To assess this, patients will undergo a dynamic chest X-ray (fluoroscopy) before and after the procedure. If diaphragm movement appears reduced afterward, a follow-up exam will be performed at 3 months to monitor the evolution. Patients presenting with a fluoroscopic abnormality at Month 3 will undergo a follow-up at Month 6. If the abnormality persists at M6, follow-up will be extended to Month 12. The study does not involve any experimental treatment or changes to standard medical care, and there are no additional risks associated with the planned exams. It is entirely observational. All data will be used anonymously to help improve the safety of current techniques.

Detailed description

Study Type This is a prospective, observational, multicenter study conducted in four electrophysiology centers. The study does not involve any experimental intervention or modification of standard care. It is based on the systematic observation of a complementary imaging exam (dynamic fluoroscopy) performed before and after a PFA procedure, as part of the routine management of atrial fibrillation. Participation Duration The maximum duration of participation for each patient is twelve (12) months. Follow-up includes: an inclusion visit with pre-procedure fluoroscopy, a post-procedure fluoroscopy performed before hospital discharge (on the day of the procedure or the following day, depending on local practices), a 3-6 and 12 month visit with fluoroscopy, only if an abnormality was detected in the post-procedure assessment. General Methodology The study aims to include 250 consecutive patients undergoing PFA for atrial fibrillation, regardless of the single-shot system used (FARAPULSE™, PULSE SELECT™, VARIPULSE™, or VOLT™), at the discretion of each operator. Dynamic fluoroscopy will be performed before the catheter ablation using a PFA system, and repeated afterward before the patient's discharge-on the same day or the following day, depending on the center's practice. The images will be stored and analyzed to assess diaphragmatic excursion (in millimeters). Exams will be considered of sufficient quality if the excursion of at least one hemidiaphragm is ≥35 mm, and optimal if ≥40 mm. Diaphragmatic impairment will be defined as an asymmetry ≥15% in cranio-caudal excursion between hemidiaphragms after the procedure. Patients with diaphragmatic impairment will be invited for a follow-up fluoroscopy at three months.

Conditions

Timeline

Start date
2025-10-01
Primary completion
2026-04-01
Completion
2027-04-01
First posted
2025-08-17
Last updated
2025-10-01

Source: ClinicalTrials.gov record NCT07127900. Inclusion in this directory is not an endorsement.